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Abstract
Background:  Resting and postprandial oxidative stress is elevated in those with metabolic
disorders such as diabetes. Antioxidant supplementation may attenuate the rise in oxidative stress
following feeding. Therefore we sought to determine the effects of acetyl L-carnitine arginate
(ALCA) on resting and postprandial biomarkers of glucose and lipid metabolism, as well as
oxidative stress.
Methods: Twenty-nine pre-diabetic men and women were randomly assigned to either 3 g·day-1
of ALCA (n = 14; 31 ± 3 yrs) or placebo (n = 15; 35 ± 3 yrs) in a double-blind design, to consume
for eight weeks. Fasting blood samples were taken from subjects both pre and post intervention.
After each fasting sample was obtained, subjects consumed a high fat, high carbohydrate meal and
additional blood samples were taken at 1, 2, 4, and 6 hours post meal. Samples were analyzed for
a variety of metabolic variables (e.g., glucose, HbA1c, lipid panel, C-reactive protein, nitrate/nitrite,
and several markers of oxidative stress). Area under the curve (AUC) was calculated for each
variable measured post meal, both pre and post intervention.
Results: ALCA, but not placebo, resulted in an increase in nitrate/nitrite (25.4 ± 1.9 to 30.1 ± 2.8
μmol·L-1) from pre to post intervention, with post intervention values greater compared to placebo
(p = 0.01). No other changes of statistical significance were noted (p > 0.05), although ALCA
resulted in slight improvements in glucose (109 ± 5 to 103 ± 5 mg·dL-1), HbA1c (6.6 ± 1.1 to 6.2 ±
1.2%), and HOMA-IR (3.3 ± 1.3 to 2.9 ± 1.2). AUC postprandial data were not statistically different
between ALCA and placebo for any variable (p > 0.05). However, nitrate/nitrite demonstrated a
moderate effect size (r = 0.35) for increase from pre (139.50 ± 18.35 μmol·L-1·6 hr-1) to post
(172.40 ± 21.75 μmol·L-1·6 hr-1) intervention with ALCA, and the magnitude of decrease following
feeding was not as pronounced as with placebo.
Conclusion: Supplementation with ALCA results in an increase in resting nitrate/nitrite in pre-
diabetics, without any statistically significant change in other metabolic or oxidative stress variables
measured at rest or post meal.
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Background
More than 70 million individuals within the United States
alone currently live with cardiovascular disease [1], while
nearly 21 million people have diabetes and 54 million are
diagnosed with pre-diabetes [2]. Oxidative stress is sug-
gested as one unifying link between cellular dysfunction
and the onset and progression of both cardiovascular [3]
and metabolic [4] disorders. Although a basal level of rad-
ical production is important for proper physiological
function [5], overexpression of radical species, either via
increased production or decreased antioxidant defense,
can result in oxidative damage to lipids, proteins, and
nucleic acids, all of which may contribute to the patho-
physiology of disease [6]. In particular, oxidative damage
to the vascular endothelium is well described [7] and is
associated with a poor cardiovascular prognosis [8].
Meals high in fat and carbohydrate that lead to hypertrig-
lyceridemia or hyperglycemia have been shown to pro-
mote an exacerbation in radical production [9] and have
been associated with increased risk for atherosclerosis and
related disorders [10]. Thus, postprandial oxidative stress
(and associated measures of triglycerides and blood glu-
cose) appears to provide more important information
related to cardiovascular and metabolic disease develop-
ment and progression [3,11].
Individuals with impaired glucose metabolism are most
susceptible to postprandial oxidative stress, as they typi-
cally experience prolonged periods of hyperglycemia [12-
14] and hypertriglyceridemia [15,16] post feeding. Eleva-
tions in blood glucose and triglycerides are directly asso-
ciated with superoxide anion production [17], a potent
and harmful radical species [18].
Antioxidant intake has been used in several studies in an
attempt to attenuate the rise in postprandial oxidative
stress. This body of work has included the study of foods
such as olive oil [19], almonds [20] and red wine [21], as
well as nutritional supplements containing vitamins and
minerals [22-24]. One antioxidant nutrient with a signifi-
cant body of literature in support of its antioxidant effects
is carnitine [25,26] which is associated with a reduction in
xanthine oxidase activity [27] and known to possess free-
radical scavenging activity [28].
A recent report by Volek and colleagues [29] demon-
strated the potential benefits of L-carnitine, L-tartrate sup-
plementation on endothelial cell function, assessed via
flow mediated dilation (FMD). The authors suggest a
potential role of nitric oxide in promoting these findings,
as nitric oxide is a signaling molecule known to facilitate
vasodilatation by acting on vascular smooth muscle cells
[30]. This appears partly supported by preliminary studies
involving carnitine supplementation and measurement of
nitric oxide in a fasted state [31-33]. However, to our
knowledge, no study has investigated the potential bene-
fits of dietary carnitine either alone or in conjunction with
L-arginine (the precursor to nitric oxide biosynthesis [34])
on circulating nitric oxide during the postprandial state,
and only that of Volek et al. [29] has included a measure
of postprandial oxidative stress (malondialdehyde).
Because nitric oxide typically decreases in response to an
increase in postprandial oxidative stress [22,35], likely
mediated by the increase in superoxide production and
associated endothelial dysfunction [36], maintenance of
nitric oxide via carnitine ingestion could be viewed as
favorable in regards to vascular function. This may be of
particular importance for those with metabolic dysfunc-
tion.
Therefore, the purpose of this study was to determine the
effects of supplementation with a novel L-arginine con-
taining form of acetyl L-carnitine supplementation
(ArginoCarn®) on postprandial oxidative stress and asso-
ciated metabolic biomarkers in a sample of pre-diabetic
men and women. We hypothesized that 1) oxidative stress
biomarkers would be increased, and nitric oxide
decreased, following ingestion of a high fat, high carbohy-
drate test meal, and 2) subjects assigned to the arginine/
carnitine supplement for eight weeks would experience
attenuation in postprandial oxidative stress and nitric
oxide changes.
Methods
Subjects
Forty men and women between the ages of 20 and 55
years were enrolled in this study. Subjects were non-smok-
ers (and not routinely exposed to passive smoke), pre-dia-
betic (fasting blood glucose: 100–125 mg·dL-1),
normolipidemic (fasting triglycerides < 200 mg·dL-1),
and free of cardiovascular, gastrointestinal, or metabolic
disorders. Subjects were not currently pregnant, not using
antioxidant supplements or drugs during the study
period, and not using any type of blood glucose or lipid
regulating medication or nutritional supplements. Sub-
jects were required to have a resting blood pressure <160/
100 mmHg and a body mass index of 25 kg·m-2 – 40
kg·m-2.
Baseline Assessment
During the first laboratory visit subjects completed health
and physical activity questionnaires. Subjects' height,
weight, circumference measurements, body mass index,
body composition (seven-site testing method [37]) using
the Siri equation [38], and resting heart rate and blood
pressure (following a 10-minute rest period) were
recorded. The same measurements were obtained follow-
ing the eight week intervention. Methods were approved
by the university committee for human subject research,Nutrition & Metabolism 2009, 6:25 http://www.nutritionandmetabolism.com/content/6/1/25
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in accordance with the Helsinki Declaration, and all sub-
jects provided both verbal and written consent.
Treatment
Following the conclusion of the above baseline tests, sub-
jects were provided with study instructions and were ran-
domly assigned in double-blind manner to one of
following conditions: Acetyl L-carnitine arginate (ALCA;
ArginoCarn®, Sigma-tau HealthScience S.p.A, Rome, Italy;
n = 20) or Placebo (cellulose; n = 20). The dosage of ALCA
was 3 g·day-1 and was taken in two divided doses with
meals (morning and evening – 3 capsules at each time).
The composition of 3 grams of ALCA provided approxi-
mately 1350 mg of acetyl L-carnitine and 1200 mg of
arginine. Arginine is a precursor to nitric oxide biosynthe-
sis [34] and has been associated with positive effects
related to vasodilatation when used in high dosages (e.g.,
15 grams) via either intravenous infusion [39,40] or oral
intake [41]. Capsules were identical in appearance and
provided to subjects in unlabeled bottles every two weeks,
for the duration of the eight week intervention. Capsule
counts upon bottle return determined compliance to
treatment.
Meal Testing (pre-intervention and post-intervention)
All subjects consumed two identical tests meals; one
before and one following the eight week intervention.
Subjects reported to the lab in the morning following a
10-hour overnight fast and a pre-meal blood sample was
collected. Subjects then consumed a high-fat, high carbo-
hydrate milkshake, made with whole milk, ice cream, and
whipping cream. The caloric load of the test meal was
based on subjects' body mass and was equivalent to 1.2
grams of both fat and carbohydrate, and 0.25 grams of
protein per kilogram. The test meal provided approxi-
mately 17 calories per kilogram of body weight. Blood
samples were collected from subjects at 1, 2, 4, and 6
hours following meal intake. Subjects remained in the lab
during the observation period and remained inactive. No
additional meals or calorie containing beverages were
allowed, although the intake of plain water was allowed
ad libitum. These exact procedures, including the test
meal, have been used in six recent investigations in our
lab without incident [42-47]
Blood Sampling
Venous blood samples (~10 mL per draw) were taken
from subjects' forearm via needle and collection tube.
These blood samples were collected pre-meal (0 hour),
and at 1, 2, 4, and 6 hour postprandial. The plasma/serum
was immediately processed and stored at -80°C until ana-
lyzed. Blood samples collected at all time points were
assayed for malondialdehyde, xanthine oxidase activity,
hydrogen peroxide, triglycerides, glucose, trolox equiva-
lent antioxidant capacity (TEAC), and nitrate/nitrite (a
surrogate marker of nitric oxide). Blood samples collected
at the pre-meal time point only were assayed for insulin,
HbA1c, total and HDL cholesterol, and C-reactive protein.
Assays were performed on the first thaw. The procedures
outlined above for meal testing and blood collection were
used both pre- and post-intervention.
Malondialdehyde was analyzed in plasma using a com-
mercially available assay (Northwest Life Science Special-
ties, Vancouver, WA) using the method described by
Jentzsch et al. [48] The intra-assay coefficient of variation
(CV) was 4.7%. Xanthine oxidase activity and hydrogen
peroxide were measured in plasma using the Amplex Red
reagent method as described by the manufacturer (Molec-
ular Probes, Invitrogen Detection Technologies, Eugene,
OR; CV = 4.1 and 4.7%, respectively). Assays for glucose,
triglycerides, and cholesterol were performed following
standard enzymatic procedures as described by the rea-
gent manufacturer (Thermo Electron Clinical Chemistry;
CV<5%). LDL cholesterol was calculated using the Fried-
wald equation as follows: LDL cholesterol = TC - HDL
cholesterol - (TAG/5). Antioxidant capacity was measured
in serum using the TEAC following procedures outlined
by the reagent provider (Sigma Chemical, St. Louis, MO;
CV = 3.7%). Nitrate/nitrite was analyzed in plasma using
a commercially available assay (Caymen Chemical, Ann
Arbor, MI; CV = 6.4%). HbA1c was analyzed in whole
blood following procedures outlined by the reagent pro-
vider (Diazyme Laboratories, Poway, CA; CV = 7.2%).
Insulin was analyzed in serum using an enzyme linked
immunosorbent assay (ELISA) following procedures out-
lined by the reagent provider (Diagnostic Systems Labora-
tories, Webster, TX; CV = 6.3%). The homeostatis model
assessment (HOMA-IR) was used as an index of insulin
resistance [49] and calculated as: [fasting glucose (mg·dL-
1) × fating insulin (μU·mL-1)]/405. C-reactive protein was
analyzed in serum using an ultra-sensitive ELISA proce-
dure as described by the manufacturer (Diagnostic Sys-
tems Laboratories, Webster, TX; CV = 5.8%).
Dietary Records
Subjects were instructed to maintain their normal diet and
to record their food and beverage intake during the seven
days preceding each test meal day (pre and post interven-
tion). Research assistants reviewed portion sizes with sub-
jects through the use of food models, and reviewed all
entries with subjects immediately upon diet record return.
The records were analyzed for total kilocalories, protein,
carbohydrate, fat, vitamins C, A, and E (Food Processor
SQL, version 9.9, ESHA Research, Salem, OR). Subjects
were given precise instructions regarding abstinence of
alcohol consumption, as well as the avoidance of strenu-
ous physical activity during the 24 hours immediately
prior to the test meal days, as such activity is known toNutrition & Metabolism 2009, 6:25 http://www.nutritionandmetabolism.com/content/6/1/25
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favorably alter glucose and lipid metabolism [50,51] and
result in lower oxidative stress [52].
Statistical Analysis
Area under the curve (AUC) was calculated for each using
the trapezoidal method (AUCG) as described in detail by
Pruessner et al. [53]. All variables were then analyzed
using a 2 (condition) × 2 (pre-post intervention) ANOVA.
Fasting (pre-meal) blood samples for all variables were
also analyzed between conditions, pre and post interven-
tion. Paired contrasts were used to further analyze effects.
Effect size calculations were made using Cohen's d. All
analyses were performed using JMP statistical software
(version 4.0.3, SAS Institute, Cary, NC). Statistical signifi-
cance was set at P = 0.05. Data are presented as mean ±
SEM.
Results
Although 40 subjects were initially enrolled in the study,
only 29 subjects were included in the data analysis due to
failure to complete the entire eight weeks of the interven-
tion or a request to be dropped from the study. It should
be noted that no subject was dropped due to an adverse
outcome associated with the ALCA or placebo supple-
mentation. Rather, loss of interest and personal issues
unrelated to the study protocol was the chief reason for
subject attrition. Of the 29 subjects remaining, compli-
ance to treatment was 93% for ALCA and 91% for pla-
cebo, and not different between conditions (p > 0.05).
No differences were noted between conditions or from
pre to post intervention in anthropometric variables, rest-
ing heart rate or blood pressure, or fasting metabolic
blood parameters (Table 1; p > 0.05; Figures 1, 2, 3). The
only exception was higher fasting nitrate/nitrite noted for
ALCA compared to placebo post intervention (30.1 ± 2.8
vs. 23.6 ± 2.1 μmol·L-1; p = 0.01). This was influenced by
the response of a portion of those subjects receiving
ALCA, as only eight of the fourteen subjects showed an
increase (greater than 5%) in fasting nitrate/nitrite values
from pre to post intervention (Figure 4). No differences
were noted regarding intake of total kilocalories, total
grams of protein, carbohydrate, fat, vitamin C intake, vita-
min E intake, or vitamin A intake (Table 2; p > 0.05). No
statistically significant differences (p > 0.05) were noted
between conditions or pre-post intervention in the AUC
for malondialdehyde (Figure 1A), xanthine oxidase activ-
ity (Figure 1B), hydrogen peroxide (Figure 1C), triglycer-
ides (Figure 2A), glucose (Figure 2B), TEAC (Figure 3A) or
nitrate/nitrite (Figure 3B). Individual subject data for per-
cent change from pre to post intervention for fasting
nitrate/nitrite values are presented in Figure 4. All effect
size calculations were trivial (r < 0.1) except for nitrate/
nitrite from pre to post intervention for ALCA, which was
considered moderate (r = 0.35). AUC data for all variables
are shown in Table 3.
Discussion
Findings from this investigation indicate that eight weeks
of supplementation with ALCA results in an increase in
resting nitrate/nitrite in pre-diabetics, but does not pro-
Table 1: Descriptive characteristics and bloodborne data of pre-diabetic subjects before and after an eight week intervention of ALCA 
or placebo
Variable Pre Intervention ALCA Post Intervention ALCA Pre Intervention Placebo Post Intervention Placebo
Age (yrs) 31 ± 3 31 ± 3 35 ± 3 35 ± 3
Height (cm) 172 ± 3 172 ± 3 169 ± 3 169 ± 3
Weight (kg) 85 ± 4 83 ± 5 91 ± 5 90 ± 4
BMI (kg·m-2) 28.5 ± 1.9 27.8 ± 1.7 31.7 ± 2.1 32.6 ± 2.4
Body Fat (%) 28 ± 2 26 ± 3 28 ± 2 27 ± 2
Waist (cm) 94 ± 4 92 ± 4 101 ± 5 100 ± 5
Hip (cm) 109 ± 4 106 ± 4 113 ± 5 111 ± 6
Waist:Hip 0.87 ± 0.05 0.87 ± 0.03 0.89 ± 0.04 0.90 ± 0.05
Resting HR (bpm) 73 ± 2 71 ± 2 73 ± 2 72 ± 3
Resting SBP (mmHg) 123 ± 1 121 ± 1 119 ± 1 118 ± 2
Resting DBP (mmHg) 79 ± 1 78 ± 1 80 ± 1 80 ± 1
Glucose (mg·dL-1) 109 ± 5 103 ± 5 112 ± 6 111 ± 5
HbA1c (%) 6.6 ± 1.9 6.2 ± 2.2 6.7 ± 1.8 6.6 ± 2.2
Insulin (μU·mL-1) 12.1 ± 1.8 11.4 ± 2.1 12.4 ± 1.9 12.7 ± 2.0
HOMA-IR 3.3 ± 1.3 2.9 ± 1.2 3.4 ± 1.4 3.5 ± 1.6
Total Cholesterol (mg·dL-1) 195 ± 13 192 ± 14 184 ± 14 179 ± 15
HDL-C (mg·dL-1) 51 ± 7 48 ± 6 47 ± 4 50 ± 5
LDL-C (mg·dL-1) 127 ± 13 132 ± 11 123 ± 8 117 ± 10
CRP (ng·mL-1) 1432 ± 342 1389 ± 328 1652 ± 408 1738 ± 425
Data are mean ± SEM.
No statistically significant differences noted (p > 0.05).Nutrition & Metabolism 2009, 6:25 http://www.nutritionandmetabolism.com/content/6/1/25
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mote significant changes in other metabolic or oxidative
stress variables measured at rest or post meal. The increase
in fasting nitrate/nitrite was influenced primarily by eight
of the fourteen subjects receiving ALCA (Figure 4), high-
lighting the variability in response to dietary supplemen-
tation with L-carnitine in regards to blood nitrate/nitrite,
a finding we have previously noted using glycine propio-
nyl-L-carnitine [33]. In reviewing subject characteristics in
an attempt to determine reasons for the discrepancies in
subject response, we noted no apparent differences
between "responders" and "non-responders" that would
lead us to suggest an association, with the possible excep-
tion of slightly lower starting values for some, but cer-
tainly not all responders. In this case, it is possible that
individuals with lower nitrate/nitrite values may respond
to a greater extent to ALCA treatment. Future work is
needed to more fully elucidate the reasons for such dis-
crepancies in individual response to ALCA treatment in
regards to fasting nitrate/nitrite levels. It is possible that a
portion of the increase in blood nitrate/nitrite could have
been due to an increase in physical activity of certain sub-
jects assigned to ALCA, as an increase in resting nitrate/
nitrite has been reported previously for individuals
involved in exercise training [54-56].
Based on the collective data we must reject our hypothesis
that ALCA would lead to favorable effects on postprandial
oxidative stress and associated biomarkers. However, our
findings of a moderate effect size for increase in the AUC
for nitrate/nitrite from pre to post intervention with ALCA
may have clinical relevance, despite the lack of statistical
significance. Of course, this hypothesis needs further
investigation, and needs replication in a larger sample of
human subjects; in particular in regards to identifying
those individuals who are responders to treatment and
those who are not.
Unlike the recent work of Volek and coworkers [29] that
included only one measure of oxidative stress (malondial-
dehyde), we included a full panel of commonly assessed
oxidative stress biomarkers within the present design. Our
failure to note any significant effect of ALCA in regards to
this panel provides convincing evidence that no treatment
effect related to postprandial oxidative stress is noted with
supplementation, at least at the dosage (3 g·day-1) and for
Table 2: Dietary data of pre-diabetic subjects during 7 days preceding a test meal
Variable Pre Intervention ALCA Post Intervention ALCA Pre Intervention Placebo Post Intervention Placebo
Kcal 2425 ± 285 2274 ± 158 2315 ± 217 2380 ± 194
Protein (g) 88 ± 13 84 ± 7 79 ± 8 80 ± 9
CHO (g) 310 ± 33 292 ± 21 275 ± 28 289 ± 26
Fat (g) 93 ± 14 85 ± 9 99 ± 11 100 ± 102
Vitamin C (mg) 102 ± 12 91 ± 16 87 ± 18 76 ± 19
Vitamin E (mg) 10 ± 8 12 ± 5 8 ± 7 7 ± 7
Vitamin A (RE) 3981 ± 1048 4240 ± 845 3745 ± 986 4214 ± 896
Data are mean ± SEM.
No statistically significant differences noted (p > 0.05).
Table 3: Postprandial area under the curve data of pre-diabetic subjects before and after an eight week intervention of ALCA or 
placebo
Variable Pre Intervention ALCA Post Intervention ALCA Pre Intervention Placebo Post Intervention Placebo
Malondialdehyde
(μmol·L-1·6 hr-1)
9.66 ± 1.33 9.39 ± 1.17 9.56 ± 1.15 9.26 ± 1.07
Xanthine Oxidase
(mU·mL-1·6 hr-1)
67.77 ± 7.70 67.45 ± 9.24 74.11 ± 8.58 76.91 ± 10.39
Hydrogen Peroxide
(μmol·L-1·6 hr-1)
84.76 ± 13.15 81.25 ± 14.87 79.65 ± 12.47 86.45 ± 15.43
Triglyceride
(mg·dL-1·6 hr-1)
585.00 ± 74.22 580.50 ± 73.84 612.95 ± 92.98 597.08 ± 70.43
Glucose
(mg·dL-1·6 hr-1)
658.00 ± 56.27 640.18 ± 73.71 683.00 ± 67.82 679.45 ± 54.46
TEAC
(mmol·L-1·6 hr-1)
3.30 ± 0.19 3.45 ± 0.18 3.25 ± 0.21 3.28 ± 0.19
Nitrate/Nitrite
(μmol·L-1·6 hr-1)
139.50 ± 18.35 172.40 ± 21.75 128.70 ± 11.75 130.45 ± 10.15
Data are mean ± SEM.
No statistically significant differences noted (p > 0.05).Nutrition & Metabolism 2009, 6:25 http://www.nutritionandmetabolism.com/content/6/1/25
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Blood malondialdehyde (A), xanthine oxidaseactivity (B), and  hydrogen peroxide (C) in pre-diabetic subjects before and  after an eight week intervention of ALCA or placebo Figure 1
Blood malondialdehyde (A), xanthine oxidaseactivity 
(B), and hydrogen peroxide (C) in pre-diabetic sub-
jects before and after an eight week intervention of 
ALCA or placebo. Data are mean ± SEM.
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Blood triglycerides (A) and glucose (B) in pre-diabetic sub- jects before and after an eight week intervention of ALCA or  placebo Figure 2
Blood triglycerides (A) and glucose (B) in pre-dia-
betic subjects before and after an eight week inter-
vention of ALCA or placebo. Data are mean ± SEM.
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the duration (8 weeks) provided. This, despite the fact that
our chosen treatment included L-arginine, a known pre-
cursor to nitric oxide biosynthesis [34], as one component
of the supplement. Whereas, the study by Volek and col-
leagues used L-carnitine, L-tartrate as the supplement of
choice [29].
Our data related to nitrate/nitrite provide partial support
for the findings of improved FMD with carnitine intake
[29], as nitric oxide is known to facilitate vasodilatation
by acting on vascular smooth muscle cells [30]. Such an
effect may be associated with favorable clinical outcomes,
as endothelial dysfunction is linked to cardiovascular
morbidity and mortality [8]. However, it is unknown
what, if any, clinical relevance both our findings and
those of Volek et al. [29] may have. This is particularly true
for the extremely small, but statistically significant find-
ings of Volek et al. [29], who noted an increase in post-
prandial (1.5 hour) FMD from 6.6% to 7.7% with
carnitine treatment as compared to a decrease in FMD
from 6.6% to 5.8% with placebo. While these findings
were noted as statistically significant, their clinical rele-
vance must be questioned, especially considering the
somewhat subjective nature of this brachial artery imag-
ing assessment. Moreover, no other differences were
noted between carnitine and placebo at the 3.0 and 4.5
hour postprandial measurement times. In fact, FMD was
actually higher for placebo at these times compared to car-
nitine. Clearly, replication of these findings is needed
before firm conclusions can be made regarding the impact
of supplemental carnitine intake on vascular health and
function. This is particularly true considering that no
other measures in this study by Volek and colleagues [29]
were noted to be significantly effected by carnitine (e.g.,
triglycerides, malondialdehyde, insulin, interleukin-6,
tumor necrosis factor-alpha).
Carnitine may promote increased or maintained nitric
oxide in two distinct manners. First, eNOS gene expres-
sion has been demonstrated to be increased within cul-
tured human endothelial cells following carnitine
incubation [25]. We have recently reported in two studies
using human subjects that oral supplementation with car-
nitine (glycine propionyl L-carnitine) increased nitrate/
nitrate at rest [32] and in response to static exercise [33].
Lofreddo and coworkers [31] have also demonstrated that
intravenous injection of propionyl L-carnitine increases
nitrate/nitrate in patients with peripheral arterial disease.
Second, the antioxidant effects of carnitine can provide
protection against nitric oxide destruction via superoxide
production [57]. L-carnitine has been shown to have
effective hydrogen peroxide and superoxide anion scav-
enging abilities [58], which may minimize the interaction
between nitric oxide and superoxide, ultimately leading to
decreased formation of peroxynitrite [57] and mainte-
Blood TEAC (A) and nitrate/nitrite (B) in pre-diabetic sub- jects before and after an eight week intervention of ALCA or  placebo Figure 3
Blood TEAC (A) and nitrate/nitrite (B) in pre-dia-
betic subjects before and after an eight week inter-
vention of ALCA or placebo. Data are mean ± SEM.
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Individual percent change data from pre to post intervention in fasting nitrate/nitrite for ALCA (A) and placebo (B) Figure 4
Individual percent change data from pre to post intervention in fasting nitrate/nitrite for ALCA (A) and pla-
cebo (B).
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nance of nitric oxide. Hence, carnitine may lead to both
the production of nitric oxide, as well as the maintenance
of existing nitric oxide.
Our hypothesis for attenuation in oxidative stress biomar-
kers with ALCA treatment was based on a sound body of
literature demonstrating antioxidant benefits of carnitine
in both humans [32,59,60] and animals [27,61,62]. Our
failure to note significant antioxidant effects related to our
chosen biomarkers could be explained in at least two
manners.
First, it is possible that the dosage of ALCA used in the
present study, in conjunction with the relatively large
nutrient load, was not adequate to provide protection
against the massive oxidative insult incurred by the test
meal. Most previous studies have simply measured oxida-
tive stress biomarkers in a rested, fasted state following
carnitine administration. Our use of the test meal may
have overwhelmed the antioxidant ability of the ALCA,
leading to our null results. This is particularly true consid-
ering that our test meal, although not of uncommon size
and composition for meals consumed by many over-
weight/obese individuals, was relatively large compared
to some previous studies [63-65]. This may have lead to
increased radical production, possibly minimizing any
positive effects of the ALCA treatment.
Second, our sample consisted of pre-diabetics, thus defi-
ciencies in postprandial glucose and lipid metabolism
likely occurred in response to the test meal. Surprisingly,
however, we noted only a minimal blood glucose
response to feeding. This is likely due to both the timing
of our measurements (i.e., first measurement occurring
one hour post feeding), as well as the inclusion of a high
amount of dietary fat to the test meal. Almost identical
findings have been reported recently by Blendea and col-
leagues [66]. In addition to being pre-diabetic, our sub-
jects were overweight or obese. We have recently noted
that obese individuals experience an exaggerated lipemic
and oxidative stress response to high fat, high carbohy-
drate feeding, as compared to normal weight subjects
[45]. This increase in blood triglyceride following feeding
is directly linked to superoxide production [67,68], likely
mediated by hypertriglyceridemic-induced neutrophilia
[69]. Circulating triglycerides may also result in acceler-
ated superoxide production from the abundance of sub-
strate processing and subsequent production of reducing
molecules (e.g., NADH, FADH2) generated with our large
meal [70]. Obese individuals also have lower plasma anti-
oxidants and higher tissue lipid levels which can lead to
an increased susceptibility to oxidative stress [71]. Hence,
our sample of pre-diabetics may have experienced too
great an increase in radical production following the
meal, further hampering the ability of the ALCA to pro-
vide measurable antioxidant effects. Future work may
consider the use of 1) a higher dosage of ALCA, 2) smaller
test meals, and 3) the use of metabolically normal test
subjects in order to further determine the potential anti-
oxidant benefits of ALCA in relation to postprandial oxi-
dative stress and associated biomarkers.
Conclusion
Eight weeks of supplementation with ArginoCarn® results
in an increase in resting nitrate/nitrite in pre-diabetic sub-
jects, which may allow for higher overall circulating
nitrate/nitrite following intake of a high kilocalorie, high
fat and carbohydrate meal. This ingredient also results in
a slight improvement in glucose metabolism, as evi-
denced by minor decreases in blood glucose, insulin, and
HbA1c (which may have been more pronounced with
longer treatment, as HbA1c has a half-life equal to approx-
imately 12 weeks [72]). However, ALCA does not result in
significant changes in other metabolic or oxidative stress
variables measured at rest or after feeding. It is possible
that a greater dosage and/or duration of treatment of
ALCA is needed for attenuation of postprandial oxidative
stress. Moreover, such factors as the size and composition
of the test meal, in addition to abnormal glucose metabo-
lism and excess body weight/fat of our test subjects, may
have contributed to the null findings. That is, any poten-
tial antioxidant effect of ALCA may have been over-
whelmed by the oxidant burden of the test meal, coupled
with potentially exacerbated radical generation and
decreased antioxidant defense of our test subjects. The
increase in nitrate/nitrite may indicate positive effects
related to vascular function. Of course, additional study is
necessary to confirm this hypothesis.
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